Up-regulation of heme oxygenase-1 after infarct initiation reduces mortality, infarct size and left ventricular remodeling: Experimental evidence and proof of concept

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Kusmic, Claudia ^a   Barsanti, Cristina ^b   Matteucci, Marco ^b   Vesentini, Nicoletta ^a   Pelosi, Gualtiero ^a   Abraham, Nader G ^c   L'Abbate, Antonio ^a,b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

^c MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cobalt protoporphyrin IX; Connexin 43; Coronary microvascular reactivity; Left ventricular vascularity; Myocardial infarction; Tin mesoporphyrin; Ventricular remodeling

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CASPASE 3; CONNEXIN 43; ENDOTHELIN 1; HEME OXYGENASE 1; PROSTAGLANDIN E2; PROTOPORPHYRIN COBALT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTERIOLAR DENSITY; ARTERY LIGATION; ARTICLE; BLOOD LEVEL; BLOOD VESSEL PARAMETERS; CAPILLARY DENSITY; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CORONARY VASCULAR RESISTANCE; ENZYME ACTIVITY; ENZYME INDUCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART RATE; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEART VENTRICLE SIZE; HYPOTENSION; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; ENZYMOLOGY; METABOLISM; MORTALITY; UPREGULATION; WISTAR RAT;

ANIMALS; HEME OXYGENASE-1; MALE; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR; UP-REGULATION; VENTRICULAR REMODELING;

EID: 84899475256     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-89     Document Type: Article

References (56)

1. Vaughan DE, Pfeffer MA. Angiotensin converting enzyme inhibitors and cardiovascular remodelling. Cardiovasc Res 1994, 28:159-165. 10.1093/cvr/28.2.159, 8143295.
2. Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 2005, 111:3411-3419. 10.1161/CIRCULATIONAHA.104.508093, 15967846.
3. Koitabashi N, Kass DA. Reverse remodeling in heart failure mechanisms and therapeutic opportunities. Nat Rev Cardiol 2011, doi:10.1038/nrcardio.2011.172.
4. Cleutjens JPMW, Blankesteijn MW, Daemen MJAP, Smits JFM. The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res 1999, 44:232-241. 10.1016/S0008-6363(99)00212-6, 10690298.
5. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004, 94:1543-1553. 10.1161/01.RES.0000130526.20854.fa, 15217919.
6. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008, 58:88-111. 10.1016/j.phrs.2008.06.007, 2642482, 18620057.
7. Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res 2009, 81:482-490. 2639132, 19050008.
8. Pelosi G, Matteucci M, Kusmic C, Vesentini N, Piccolomini F, Viglione F, Trivella MG, L'Abbate A. Time course of TUNEL nuclear positivity of cardiomyocytes in a chronic rat model of coronary occlusion with and without reperfusion. Cardiovasc Res 2010, 87:S76.
9. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Ann Rev Physiol 2010, 72:19-44.
10. Yet SF, Tian R, Layne MD, Wang ZY, Maemura K, Solovyeva M, Ith B, Melo LG, Zhang L, Ingwall JS, Dzau VJ, Lee ME, Perrella MA. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res 2001, 89:168-173. 10.1161/hh1401.093314, 11463724.
11. Wang G, Hamid T, Keith RJ, Zhou G, Partridge CR, Xiang X, Kingery JR, Lewis RK, Li Q, Rokosh DG, Ford R, Spinale FG, Riggs DW, Srivastava S, Bhatnagar A, Bolli R, Prabhu SD. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation 2010, 121:1912-1925. 10.1161/CIRCULATIONAHA.109.905471, 2917269, 20404253.
12. Juhasz B, Varga B, Czompa A, Bak I, Lekli I, Gesztelyi R, Zsuga J, Kemeny-Beke A, Antal M, Szendrei L, Tosaki A. Postischemic cardiac recovery in heme oxygenase-1 transgenic ischemic/reperfused mouse myocardium. J Cell Mol Med 2011, 15:1973-1982. 10.1111/j.1582-4934.2010.01153.x, 20716121.
13. Melo LG, Agrawal R, Zhang L, Rezvani M, Mangi AA, Ehsan A, Griese DP, Dell'Acqua G, Mann MJ, Oyama J, Yet SF, Layne MD, Perrella MA, Dzau VJ. Gene therapy strategy for long-term myocardial protection using adenoassociated virus-mediated delivery of heme oxygenase gene. Circulation 2002, 105:602-607. 10.1161/hc0502.103363, 11827926.
14. Liu X, Pachori AS, Ward CA, Davis JP, Gnecchi M, Kong D, Zhang L, Murduck J, Yet SF, Perrella MA, Pratt RE, Dzau VJ, Melo LG. Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. FASEB J 2006, 20:207-216. 10.1096/fj.05-4435com, 16449792.
15. Liu X, Simpson JA, Brunt KR, Ward CA, Hall SR, Kinobe RT, Barrette V, Tse MY, Pang SC, Pachori AS, Dzau VJ, Ogunyankin KO, Melo LG. Preemptive heme oxygenase-1 gene delivery reveals reduced mortality and preservation of left ventricular function 1 yr after acute myocardial infarction. Am J Physiol Heart Circ Physiol 2007, 293:H48-H49. 10.1152/ajpheart.00741.2006, 17322421.
16. Lakkisto P, Kytö V, Forsten H, Siren JM, Segersvärd H, Voipio-Pulkki LM, Tikkanen I. Heme oxygenase-1 and carbon monoxide promote neovascularization after myocardial infarction by modulating the expression of HIF-1alpha, SDF-1alpha and VEGF-B. Eur J Pharmacol 2010, 635:156-164. 10.1016/j.ejphar.2010.02.050, 20303947.
17. Kappas A, Drummond GS. Control of heme metabolism with synthetic metalloporphyrins. J Clin Invest 1986, 77:335-339. 10.1172/JCI112309, 423351, 3511095.
18. Smith A, Alam J, Escriba PV, Morgan WT. Regulation of heme oxygenase and metallothionein gene expression by the heme analogs, cobalt-, and tin-protoporphyrin. J Biol Chem 1993, 268:7365-7371.
19. Lin HH, Chen YH, Chang PF, Lee YT, Yet SF, Chau LY. Heme oxygenase-1 promotes neovascularization in ischemic heart by coinduction of VEGF and SDF-1. J Mol Cell Cardiol 2008, 45:44-55. 10.1016/j.yjmcc.2008.04.011, 18534615.
20. Sardana MK, Kappas A. Dual control mechanism for heme oxygenase: Tin (IV)-protoporphyrin potently inhibits enzyme activity while markedly increasing content of enzyme protein in liver. Proc Natl Acad Sci U S A 1987, 84:2464-2468. 10.1073/pnas.84.8.2464, 304672, 3470805.
21. Delaney JK, Mauzerall D, Drummond GS, Kappas A. Photophysical properties of Sn-porphyrins: potential clinical implications. Pediatrics 1988, 81:498-504.
22. DeSandre GH, Wong RJ, Morioka I, Contag CH, Stevenson DK. The effectiveness of oral tin mesoporphyrin prophylaxis in reducing bilirubin production after an oral heme load in a transgenic mouse model. Biol Neonat 2005, 89:139-146.
23. Kim DH, Burgess AP, Li M, Tsenovoy PL, Addabbo F, McClung JA, puri N, Abraham NG. Heme oxygenase-mediated increases in adiponectin decrease fat content and inflammatory cytokines tumor necrosis factor-alpha and interleukin-6 in Zucker rats and reduce adipogenesis in human mesenchymal stem cells. J Pharmacol Exp Ther 2008, 325:833-840. 10.1124/jpet.107.135285, 18334666.
24. Walker MJ, Curtis MJ, Hearse DJ, Campbell RW, Janse MJ, Yellon DM, Cobbe SM, Coker SJ, Harness JB, Harron DW, Higgins AJ, Julian DG, Lab MJ, Manning AS, Northover BJ, Parratt JR, Riemersma RA, Riva E, Russell DC, Sheridan DJ, Winslow E, Woodward B. The Lambeth Conventions: guidelines for the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiovasc Res 1988, 22:447-455. 10.1093/cvr/22.7.447, 3252968.
25. Demiryurek AT, Yildiz G, Esiyok S, Altug S. Protective effects of poly (ADP-ribose) synthase inhibitors on digoxin-induced cardiotoxicity in guinea-pig isolated hearts. Pharmacol Res 2002, 45:189-194. 10.1006/phrs.2002.0945, 11884214.
26. Miranda A, Costa-E-Sousa RH, Werneck-De-Castro JPS, Mattos EC, Olivares EL, Ribeiro VP, Silva MG, Goldenberg R, Campos-de-Carbalho AC. Time course of echocardiographic and electrocardiographic parameters in myocardial infarct in rats. Ann Braz Acad Sci 2007, 70:639-648.
27. Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, Maistre G, Escolano S, Thomas D, Komajda M. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997, 18:254-258. 10.1093/oxfordjournals.eurheartj.a015228, 9043842.
28. Moe GW, Rouleau JL, Nguyen QT, Cernacek P, Stewart DJ. Role of endothelins in congestive heart failure. Can J Physiol Pharmacol 2003, 81:588-597. 10.1139/y03-011, 12839270.
29. Degousee N, Fazel S, Angoulvant D, Stefanski E, Pawelzik SC, Korotkova M, Arab S, liu P, Lindsay TF, Zhuo S, Butany J, Li RK, Audoly L, Schmidt R, Angioni C, Geisslinger G, Jakobsson PJ, Rubin BB. Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 2008, 117:1701-1710. 10.1161/CIRCULATIONAHA.107.749739, 18347209.
30. Kusmic C, Lazzerini G, Coceani F, Barsacchi R, L'Abbate A, Sambuceti G. Paradoxical coronary microcirculatory constriction during ischemia: a synergic function for nitric oxide and endothelin. Am J Physiol Heart Circ Physiol 2006, 291:H1814-H1821. 10.1152/ajpheart.00220.2006, 16648189.
31. Motterlini R, Foresti R, Intaglietta M, Winslow RM. NO-mediated activation of heme oxygenase: Endogenous cytoprotection against oxidative stress to endothelium. Am J Physiol Heart Circ Physiol 1996, 270:H107-H114.
32. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res 1979, 44:503-512. 10.1161/01.RES.44.4.503, 428047.
33. Chen L, Chen CX, Gan XT, Beier N, Scholz W, Karmazyn M. Inhibition and reversal of myocardial infarction-induced hypertrophy and heart failure by NHE-1 inhibition. Am J Physiol Heart Circ Physiol 2004, 286:H381-H387.
34. Hou Y, Huang C, Cai X, Zhao J, Guo W. Improvements in the establishment of a rat myocardial infarction model. J Int Med Res 2011, 39:1284-1292. 10.1177/147323001103900416, 21986130.
35. De Serro-Azul LG, Moffa PJ, Mignone CA, De Carvalho Filho ET, Pileggi F, Tranchesi J. Vectorcardiographic diagnosis of left anterior divisional block in myocardial infarct. Rev Paul Med 1974, 83:267-273.
36. Santos PEB, Masuda MO. The electrocardiogram of rats with an old extensive myocardial infarction. Braz J Med Biol Res 1991, 24:1173-1177.
37. Spragg DD, Akar FG, Helm RH, Tunin RS, Tomaselli GF, Kass DA. Abnormal conduction and repolarization in late-activated myocardium of dyssynchronously contracting hearts. Cardiovasc Res 2005, 67:77-86. 10.1016/j.cardiores.2005.03.008, 15885674.
38. Thomas SA, Schuessler RB, Berul CI, Beardslee MA, Beyer EC, Mendelsohn ME, Saffitz JE. Disparate effects of deficient expression of connexin43 on atrial and ventricular conduction evidence for chamber-specific molecular determinants of conduction. Circulation 1998, 97:686-691. 10.1161/01.CIR.97.7.686, 9495305.
39. Jalife J, Morley GE, Vaidya D. Connexin and impulse propagation in the mouse heart. J Cariovasc Electrophysiol 1999, 10:1649-1663.
40. Danik SB, Liu F, Zhang J, Suk HJ, Morley GE, Fishman GI, Gutstein DE. Modulation of cardiac gap junction expression and arrhythmic susceptibility. Circ Res 2004, 95:1035-1041. 10.1161/01.RES.0000148664.33695.2a, 2956442, 15499029.
41. Morley GE, Danik SB, Bernstein B, Sun Y, Rosner G, Gutstein DE, Fishman GI. Reduced intercellular coupling leads to paradoxical propagation across the Purkinje-ventricular junction and aberrant myocardial activation. Proc Natl Am Soc 2005, 102:4126-4129.
42. Bacharova L, Plandorova J, Klimas J, Krenek P, Kyselovic J. Discrepancy between increased left ventricular mass and " normal" QRS voltage is associated with decreased connexin 43 expression in early stage of left ventricular hypertrophy in spontaneously hypertensive rats. J Electrocardiol 2008, 41:730-734. 10.1016/j.jelectrocard.2008.01.013, 18358486.
43. Guerrero PA, Schuessler RB, Davis LM, Beyer EC, Johnson CM, Yamada KA, Saffitz JE. Slow ventricular conduction in mice heterozygous for a connexin43 null mutation. J Clin Invest 1997, 99:1991-1998. 10.1172/JCI119367, 508024, 9109444.
44. Yuan MJ, Huang H, Tang YH, Wu G, Gu YW, Chen YJ, Huang CX. Effects of ghrelin on Cx43 regulation and electrical remodeling after myocardial infarction in rats. Peptides 2011, 32:2357-2361. 10.1016/j.peptides.2011.10.004, 22008733.
45. Wen H, Jliang H, He B, Chen J, Zhao D. Carvedilol ameliorates the decreases in connexin 43 and ventricular fibrillation threshold in rats with myocardial infarction. Tohoku J Exp Med 2009, 218:121-127. 10.1620/tjem.218.121, 19478468.
46. Peters NS, Coromilas J, Severs NJ, Wit AL. Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation 1997, 95:988-996. 10.1161/01.CIR.95.4.988, 9054762.
47. Peters NS, Green CR, Poole-Wilson PA, Severs NJ. Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation 1993, 88:864-875. 10.1161/01.CIR.88.3.864, 8394786.
48. Lindsey ML, Escobar GP, Mukherjee R, Goshorn DK, Bruce JA, Mains IM, Hendrick JK, Hewett KW, Gourdie RG, Matrisian LM, Spinale FG. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation 2006, 113:2919-2928. 10.1161/CIRCULATIONAHA.106.612960, 16769909.
49. Lerner DL, Yamada KA, Schuessler RB, Saffitz JE. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation 2000, 101:547-552. 10.1161/01.CIR.101.5.547, 10662753.
50. Poelzing S, Rosenbaum DS. Altered connexin43 expression produces arrhythmia substrate in heart failure. Am J Physiol Heart Circ Physiol 2004, 287:H1762-H1770. 10.1152/ajpheart.00346.2004, 15205174.
51. Heras M, Sanz G, Roig E, Perez-Villa F, Recasens L, Serra A, Betriu A. Endothelial dysfunction of the non-infarct related, angiographically normal, coronary artery in patients with an acute myocardial infarction. Eur Heart J 1996, 17:715-720. 10.1093/oxfordjournals.eurheartj.a014938, 8737102.
52. Uren NG, Crake T, Lefroy DC, de Silva R, Davies GJ, Maseri A. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med 1994, 331:222-227. 10.1056/NEJM199407283310402, 7832835.
53. Lakkisto P, Siren JM, Kyto V, Forsten H, Laine M, Pulkki K, Tikkanen I. Heme oxygenase-1 induction protects the heart and modulates cellular and extracellular remodelling after myocardial infarction in rats. Exp Biol Med 2011, 326:1437-1448.
54. L'Abbate A, Neglia D, Vecoli C, Novelli M, Ottaviano V, Baldi S, Barsacchi R, Paolicchi A, Masiello P, Drummond GS, McClung JA, Abraham NG. Beneficial effect of heme oxygenase-1 expression on myocardial ischemia-reperfusion involves an increase in adiponectin in mildly diabetic rats. Am J Physiol Heart Circ Physiol 2007, 293:H3532-H3541. 10.1152/ajpheart.00826.2007, 17906103.
55. Kusmic C, L'Abbate A, Sambuceti G, Drummond G, Barsanti C, Matteucci M, Cao J, Piccolomini F, Cheng J, Abraham NG. Myocardial perfusion in chronic diabetic mice by the up-regulation of pLKB1 and AMPK signaling. J Cell Biochem 2010, 109:1033-1044. 3723413, 20108250.
56. Schildknecht S, Ullrich V. Peroxynitrite as regulator of vascular prostanoid synthesis. Arch Biochem Biophys 2009, 484:183-189. 10.1016/j.abb.2008.10.023, 18983814.